Joon Sang Lee

Yonsei University — South Korea

Biochemistry, Genetics and Molecular Biology · Life Sciences

13h-index593citations83works3.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(12), Helminth infection and control(10), Parasites and Host Interactions(9), Advanced Breast Cancer Therapies(9), Cancer Genomics and Diagnostics(7)

Publications83 total

Biomarker analysis from a Phase 1/1b study of tusamitamab ravtansine in patients with advanced non-small cell lung cancer
Translational Oncology·2025· 1 citedOpen Access
Abstract 6064: Multiomics preclinical characterization of SAR445877, an anti-PD-1 antibody-IL-15 mutein fusion protein with robust anti-tumor efficacy as monotherapy
Cancer Research·2025
Nature's nanofactories: biogenic synthesis of metal nanoparticles for sustainable technologies
Green Chemistry Letters and Reviews·2025· 12 citedOpen Access
Classification of the Tumor Immune Microenvironment Using Machine-Learning-Based CD8 Immunophenotyping As a Potential Biomarker for Immunotherapy and TGF-β Blockade in Nonsmall Cell Lung Cancer
AI in Precision Oncology·2024· 3 citedOpen Access
Abstract 2053: Spatiotemporal tumor immune modulation by localized delivery of cancer therapeutics using an implantable microdevice
Cancer Research·2024
Abstract 5485: Spatial characterization of the immunosuppressive tumor microenvironment in estrogen receptor positive breast cancer at single cell level
Cancer Research·2024
Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (<scp>TGFβ)</scp> inhibitor <scp>SAR439459</scp> as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors
Clinical and Translational Science·2024· 6 citedOpen Access
Abstract CT213: Biomarker analysis from Phase 1/2 study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC)
Cancer Research·2023
Abstract 3649: Elucidating the role of CXCR4-CXCL12 in the tumor microenvironment of ER+ breast cancer samples using the Akoya PhenoCycler-Fusion System
Cancer Research·2023· 1 cited
Data from SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
2023Open Access
Supplementary Data from SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
2023Open Access
Data from SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
2023Open Access
Supplementary RNAseq Data from SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
2023Open Access
Supplementary Data from SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
2023Open Access
Supplementary RNAseq Data from SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
2023Open Access
926 Evaluating diverse deconvolution methods for tumor spatial transcriptomic datasets
Regular and Young Investigator Award Abstracts·2022Open Access
Abstract CT517: Amcenestrant, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/HER2- advanced breast cancer (aBC): combined biomarker analyses from a Phase 1/2 study in postmenopausal women and a Phase 1 study in postmenopausal Japanese women
Cancer Research·2022· 1 cited
Abstract P1-17-11: Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer
Cancer Research·2022· 7 cited
Abstract P4-02-08: Amcenestrant in combination with CDK4/6 inhibitor palbociclib demonstrates synergistic anti-tumor activity in ER+ endocrine-resistant breast cancer xenograft models
Cancer Research·2022· 2 cited
284 Integrated molecular characterization of primary resistance mechanisms to immune checkpoint blockade in advanced non-small cell lung carcinoma (a-NSCLC)
Regular and Young Investigator Award Abstracts·2021Open Access
page 1 of 5Next →

Frequent Co-authors

Han Jong Rim(14), Kyoung Hwan Joo(9), Hongyu Zhao(8), Fangxian Sun(4), Jack Pollard(4), Monsif Bouaboula(4), Xiting Yan(4), Maysoun Shomali(3), Dinesh S. Bangari(3), Laurent Debüssche(3), D.H. Ballard(3), Chatchawit Aporntewan(3), Ji Young Lee(3), Zheyang Wu(3), Wei Zheng(3), Marina Celanovic(3), Nils Ternès(3), Hong Wang(3), Byong Seol Seo(2), Bon Yong Koo(2)